HOUSTON – A former Novo employee is claiming the company is using a non-compete agreement to prevent her from working on "revolutionary" hemophilia gene therapy for another pharmaceutical business.
Julie Golla filed a complaint Jan. 8 in the Houston Division of the Southern District of Texas against Novo Nordisk Inc., seeking a declaratory judgment.
Golla, a 25-year veteran of the pharmaceutical field, began working for Novo in November of 2018 as a senior hemophilia therapy manager for the company's Factor VIII replacement therapies. On Jan. 7, Golla announced her resignation and intention to work for BioMarin in hemophilia gene therapy. In her complaint, she alleges Novo is attempting to use a non-competition agreement to "restrain" her from working at BioMarin on a potential "revolutionary gene therapy" for hemophilia patients.
Golla seeks monetary and all other proper relief. She is represented by Matthew Ray of Loewinsohn Flegle Deary Simon LLP in Dallas.
Houston Division of the Southern District of Texas case No. 4:20-CV-00071